1. Home
  2. ALX vs WGS Comparison

ALX vs WGS Comparison

Compare ALX & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexander's Inc.

ALX

Alexander's Inc.

HOLD

Current Price

$276.89

Market Cap

1.3B

Sector

Real Estate

ML Signal

HOLD

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

HOLD

Current Price

$61.71

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALX
WGS
Founded
1928
2017
Country
United States
United States
Employees
N/A
1300
Industry
Real Estate Investment Trusts
Retail: Computer Software & Peripheral Equipment
Sector
Real Estate
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
ALX
WGS
Price
$276.89
$61.71
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$120.71
AVG Volume (30 Days)
20.2K
830.5K
Earning Date
05-04-2026
05-04-2026
Dividend Yield
7.20%
N/A
EPS Growth
N/A
N/A
EPS
0.91
N/A
Revenue
$213,183,000.00
N/A
Revenue This Year
N/A
$29.98
Revenue Next Year
N/A
$25.92
P/E Ratio
$302.46
$1,251.58
Revenue Growth
N/A
N/A
52 Week Low
$201.28
$32.21
52 Week High
$281.56
$170.87

Technical Indicators

Market Signals
Indicator
ALX
WGS
Relative Strength Index (RSI) 61.60 48.47
Support Level $228.12 $55.76
Resistance Level $281.56 $63.31
Average True Range (ATR) 6.90 4.29
MACD -0.41 -0.85
Stochastic Oscillator 68.28 20.98

Price Performance

Historical Comparison
ALX
WGS

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: